The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

doi:10.4081/oncol.2017.324

Review

. 2017 Mar 17;11(1):324.

doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3.

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

Aurelio Bartolome Castrellon¹, Ihor Pidhorecky², Vicente Valero³, Luis Estuardo Raez⁴

Affiliations

¹ Breast Cancer Research, Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL.
² Surgical Oncology Services & Pancreaticobiliary Center, Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL.
³ Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX.
⁴ Hematology/Oncology and Medical Director of Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL, USA.

PMID: 28382189
PMCID: PMC5365000
DOI: 10.4081/oncol.2017.324

Review

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

Aurelio Bartolome Castrellon et al. Oncol Rev. 2017.

. 2017 Mar 17;11(1):324.

doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3.

Authors

Aurelio Bartolome Castrellon¹, Ihor Pidhorecky², Vicente Valero³, Luis Estuardo Raez⁴

Affiliations

¹ Breast Cancer Research, Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL.
² Surgical Oncology Services & Pancreaticobiliary Center, Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL.
³ Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX.
⁴ Hematology/Oncology and Medical Director of Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL, USA.

PMID: 28382189
PMCID: PMC5365000
DOI: 10.4081/oncol.2017.324

Abstract

Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT.

Keywords: Breast cancer; neoadjuvant chemotherapy; platinum agents.

PubMed Disclaimer

Cited by

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Jank P, et al. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020. PLoS One. 2020. PMID: 32841306 Free PMC article.
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
Ayhan S, Hancerliogullari N, Guney G, Gozukucuk M, Caydere M, Guney SS, Tokmak A, Ustun Y. Ayhan S, et al. J Ovarian Res. 2023 Sep 2;16(1):184. doi: 10.1186/s13048-023-01259-2. J Ovarian Res. 2023. PMID: 37660125 Free PMC article.
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, Chisanga D, Shi W, Collins I, Baron-Hay S, Patil S, Lindeman G, Khasraw M. Murphy C, et al. PLoS One. 2019 Feb 14;14(2):e0210891. doi: 10.1371/journal.pone.0210891. eCollection 2019. PLoS One. 2019. PMID: 30763338 Free PMC article. Clinical Trial.
Recent Advances in the Treatment of Breast Cancer.
Tong CWS, Wu M, Cho WCS, To KKW. Tong CWS, et al. Front Oncol. 2018 Jun 14;8:227. doi: 10.3389/fonc.2018.00227. eCollection 2018. Front Oncol. 2018. PMID: 29963498 Free PMC article. Review.
Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis.
Li J, Shen G, Wang M, Huo X, Zhao F, Ren D, Zhao Y, Zhao J. Li J, et al. Clin Exp Med. 2023 Sep;23(5):1489-1499. doi: 10.1007/s10238-022-00894-1. Epub 2022 Sep 24. Clin Exp Med. 2023. PMID: 36152119 Review.

See all "Cited by" articles

References

1. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071. - PMC - PubMed
1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48. - PubMed
1. Lin NU, Claus E, Sohl J, Razzak AR, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 2008;113:2638-45. - PMC - PubMed
1. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011;29:2628-34. - PMC - PubMed
1. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071. - PMC - PubMed

[2] Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071. - PMC - PubMed

[3] Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48. - PubMed

[4] Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48. - PubMed

[5] Lin NU, Claus E, Sohl J, Razzak AR, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 2008;113:2638-45. - PMC - PubMed

[6] Lin NU, Claus E, Sohl J, Razzak AR, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 2008;113:2638-45. - PMC - PubMed

[7] Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011;29:2628-34. - PMC - PubMed

[8] Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011;29:2628-34. - PMC - PubMed

[9] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. - PubMed

[10] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

Affiliations

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources